Modeling of pharmacokinetics of ganciclovir

Lung transplantation is a life-saving surgery for people with severe lung diseases such as cystic fibrosis, pulmonary fibrosis, or chronic obstructive pulmonary disease. After transplantation, recipients take an antiviral medicine called ganciclovir intravenously to prevent serious viral infections (particularly cytomegalovirus) which can threaten the transplanted lung. However, the right dose of ganciclovir varies between individuals depending on how their kidneys process the drug. This study examines the pharmacokinetics of ganciclovir — how the drug moves through the body over time — in lung transplant recipients, to understand what factors influence drug levels and to develop a more personalised dosing approach. Better dosing means more effective viral prevention with fewer side effects. You may be eligible if you have undergone a lung transplant and have been receiving intravenous ganciclovir twice daily for at least 48 hours after your transplant. Those with incomplete medical records are not eligible.